Risks and side effects of islet transplantation

被引：78

作者：

Ryan E.A. ^{[1
]}

Paty B.W. ^{[1
]}

Senior P.A. ^{[1
]}

Shapiro A.M.J. ^{[1
]}

机构：

[1] Clinical Islet Transplant Program, Edmonton, Alta. T6G 2C8

来源：

Current Diabetes Reports | 2004年 / 4卷 / 4期

关键词：

Tacrolimus; Hypoglycemia; Sirolimus; Portal Vein Thrombosis; Islet Transplantation;

D O I：

10.1007/s11892-004-0083-8

中图分类号：

学科分类号：

摘要：

Islet transplantation can deliver stable glycemic control, relief from recurrent severe hypoglycemia, and insulin independence. Accessing the portal vein via the percutaneous hepatic approach carries the risk of bleeding, and the infusion of islets a risk of portal vein thrombosis. In the long term, common minor problems with immunosuppression are mouth ulcers, diarrhea, and acne. Longer-term risks include malignancy and serious infection, both rare to date in clinical islet transplantation. Sensitization to donor antigens may also occur. The long-term diabetes complications may stabilize, but of this aspect little is known to date. In the short term, there may be some elevation of serum cholesterol and blood pressure, in some patients there has been a decline in renal function, and in a few, acute retinal bleeds. For most, improvement in glucose control with resolution of glycemic lability and hypoglycemia, has been a net benefit Copyright © 2004 by Current Science Inc.

引用

页码：304 / 309

页数：5

共 55 条

[51]

Paty B.W., Ryan E.X., Shapiro A.M.J., Et al., Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence, Diabetes, 51, pp. 3428-3434, (2002)

[52]

Kendall D.M., Teuscher A.U., Robertson R.P., Defective glucagon secretion during sustained hypoglycemia following successful islet allo- and autotransplantation in humans, Diabetes, 46, pp. 23-27, (1997)

[53]

Paty B.W., Lanz K., Kendall D.M., Et al., Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation, Transplantation, 72, pp. 1103-1107, (2001)

[54]

Gupta V., Wahoff D.C., Rooney D.P., Et al., The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined, Diabetes, 46, pp. 28-33, (1997)

[55]

Kiberd B., Estimating the benefits of solitary pancreas and islet cell transplantation in type 1 diabetes mellitus, Can. J. Diabetes Care, 25, SUPPL. 2, pp. 96-102, (2001)

← 1 2 3 4 5 6 →